During the past decade, Parkview Research Center conducted 39 clinical trials. In the 10-year time frame, 39 clinical trials started and 23 clinical trials were completed, i.e. on average, 59% percent of trials that started reached the finish line to date. In the past 5 years, 11 clinical trials started and 18 clinical trials were completed. i.e. 163.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Parkview Research Center" #1 sponsor was "Abbott Medical Devices" with 6 trials, followed by "Incyte Corporation" with 4 trials sponsored, "Sumitomo Pharma Oncology, Inc." with 4 trials sponsored, "Boston Scientific Corporation" with 2 trials sponsored and "Celgene" with 2 trials sponsored. Other sponsors include 29 different institutions and companies that sponsored additional 35 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Parkview Research Center" #1 collaborator was "National Heart, Lung, and Blood Institute (NHLBI)" with 2 trials as a collaborator, "AbbVie" with 1 trials as a collaborator, "Abbott" with 1 trials as a collaborator, "Alliance Foundation Trials, LLC." with 1 trials as a collaborator and "American Heart Association" with 1 trials as a collaborator. Other collaborators include 8 different institutions and companies that were collaborators in the rest 18 trials.

According to Clinical.Site data, the most researched conditions in "Parkview Research Center" are "Atrial Fibrillation" (4 trials), "Heart Failure" (4 trials), "Stroke" (4 trials), "Breast Cancer" (3 trials) and "Ischemic Stroke" (3 trials). Many other conditions were trialed in "Parkview Research Center" in a lesser frequency.

Most popular intervention types in "Parkview Research Center" are "Drug" (31 trials), "Device" (13 trials), "Other" (4 trials), "Biological" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Bevacizumab" (4 trials), "Carboplatin" (4 trials), "Gemcitabine" (4 trials) and "Irinotecan" (4 trials). Other intervention names were less common.

The vast majority of trials in "Parkview Research Center" are 48 trials for "All" genders, 3 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Parkview Research Center". undefined are not yet recruiting, 8 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 28 completed trials in Parkview Research Center, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in Parkview Research Center, 7 "Phase 1" clinical trials were conducted, 16 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 9 trials that are defined as “Not Applicable".